Views & Analysis | Perspectives on pharma industry issues

R&D

Alzheimer's research is moving toward more selective targets

As we mark World Alzheimer’s Day, it is worth reflecting on the progress made in recent years.

Market Access

$100 notes in pill bottle on aquamarine background with spilled pills

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access

From first approval to lasting value: What sets successful e...

Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.

Market Access

drug pricing in the UK, pills overlain on map

Request to look further into NICE non-submissions in the fut...

Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.

R&D

Changing Faces: Board of Director and Advisory Board hires, ...

Boardrooms, Advisory Boards, and governance teams saw plenty of activity in August.

Articles

The digital age in live programmes for healthcare profession...

On our final day in our digital month, Nick Willhoft discusses live programmes for healthcare professionals, including his own top ten digital innovations. It is a blast of fresh air to have a client with an ambitious schedule of stand-alone and congress-affiliated...

Articles

Health lab - bringing innovation to our digital communicatio...

Leigh Householder shares her thoughts on how pharma marketers can learn from innovative approaches used in others sectors of their organisation in the first of a two-part article. Earlier this year, I overheard two pharmaceutical executives talking about the personal impact of our industry’s faltering reputation...

Articles

Decision making and negotiation part two: M&As and fund-rais...

In the final part of Jean-Louis Roux Dit Buisson’s decision-making articles, he explores the negotiations involved in mergers, acquisitions and fund-raising. Today we are faced with the price to be paid for an acquisition. Literature reports that about 70% of all M&As projects...

Sales & Marketing

The patient communication crisis pharma can no longer ignore

Industry's significant investments in patient engagement are only effective if patients trust the communication enough to answer in the first place.

Sales & Marketing

Wooden pawns representing number of employees

Headcount is not a growth strategy

Deciding when, where, and how quickly to add headcount is rarely straightforward.

Digital

Pharma brands face golden opportunity to extend supply chain...

People are ready for technology that verifies authenticity and provides helpful information directly from the medicinal product itself.

Digital

Changing Faces: Digital and supplier hires, August 2026

Digital health, clinical technology, contract services, and life sciences suppliers all saw notable leadership changes last month.

Market Access

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access